Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Non-Current Liabilities (2021 - 2024)

Relay Therapeutics (RLAY) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $11.4 million as the latest value for Q1 2024.

  • On a quarterly basis, Other Non-Current Liabilities fell 63.75% to $11.4 million in Q1 2024 year-over-year; TTM through Mar 2024 was $11.4 million, a 63.75% decrease, with the full-year FY2023 number at $13.2 million, down 59.21% from a year prior.
  • Other Non-Current Liabilities was $11.4 million for Q1 2024 at Relay Therapeutics, down from $13.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $50.5 million in Q3 2021 to a low of $11.4 million in Q1 2024.
  • A 4-year average of $35.8 million and a median of $37.6 million in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: fell 5.37% in 2022, then crashed 63.75% in 2024.
  • Relay Therapeutics' Other Non-Current Liabilities stood at $50.3 million in 2021, then tumbled by 35.58% to $32.4 million in 2022, then crashed by 59.21% to $13.2 million in 2023, then dropped by 13.87% to $11.4 million in 2024.
  • Per Business Quant, the three most recent readings for RLAY's Other Non-Current Liabilities are $11.4 million (Q1 2024), $13.2 million (Q4 2023), and $28.0 million (Q3 2023).